Johnson & Johnson Inks $2.2B Deal for Eye Drug Developer Ollin Biosciences
Johnson & Johnson will acquire Ollin Biosciences for $2.2 billion upfront and secure $750 million from Blackstone for Phase 3 eye trials.
Last updated: 2026-11-16 22:59:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Johnson & Johnson (JNJ) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $282.67, with a market capitalization of $687.89B and a P/E ratio of 42.74. Over the past 52 weeks, its price has ranged from $195.90 to $290.37. This page covers its latest market performance, valuation, price trends and company information.
$687.89B | |
$288.99 | |
$290.37 | |
$282.33 | |
$285.75 | |
6.10M | |
7.12M | |
42.74 | |
$290.37 | |
$195.90 | |
1.85% | |
12-28 |
Johnson & Johnson (JNJ) is trading at $282.78 in after-hours trading as of 2026-11-16 22:57:00, up 0.04% ($0.10) from the regular-session close of $282.67.
After-hours trading shows how investors are pricing JNJ after the regular session closes. The current after-hours price is near the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Johnson & Johnson (JNJ) moved from $272.32 to $282.67, representing a gain of 3.80% ($10.35).
The stock traded between $265.55 and $290.37 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 7.62 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 91.9%
JNJ is currently trading at $282.67, placing it 91.9% of the way from its 52-week low of $195.90 to its 52-week high of $290.37. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 140,800 |
| CEO | Joaquin Duato |
| Founded | 1886 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for Johnson & Johnson.
Dividend | |
|---|---|
| Ex-Dividend Date | Nov 24, 2026 |
| Payment Date | Dec 8, 2026 |
| Dividend Per Share | $1.34 |
Latest news related to Johnson & Johnson and JNJ stock.
Johnson & Johnson will acquire Ollin Biosciences for $2.2 billion upfront and secure $750 million from Blackstone for Phase 3 eye trials.
Specifically, Blackstone will finance the Phase 3 clinical program of OLN324, including wet age-related macular degeneration and diabetic macular edema, following the expected closing of the acquisition of Ollin
Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., ("Ollin") a clinical-stage biopharmaceutical company developing therapies for
https://www.ft.com/content/450100ba-074c-46a6-b962-89dbef146135?FTCamp=engage/CAPI/app/Channel_Refinitiv//B2B
The article recommends five dividend stocks suitable for long-term buy-and-hold investors: Johnson & Johnson, Medtronic, Procter & Gamble, Federal Realty Investment Trust, and Realty Income. All five companies have strong dividend track records with at least 32 years of consecutive annual increases, combined with well-run underlying businesses that generate reliable income streams.
Eligible investors can buy real shares of Johnson & Johnson (JNJ) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to JNJ, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between JNJ shares and USD.
JNJ Shares to USD
1.00 JNJ shares = 282.672 USD
Calculations are estimates based on the latest available price and are for reference only.